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Background: Angiopoietin-1 (Ang-1) is an essential mediator of angiogenesis that establishes vascular integrity,
and angiopoietin-2 (Ang-2) acts as its natural inhibitor. We considered that angiopoietin might be important in
bronchial asthma.
Methods: In total, 35 patients with asthma and 20 healthy subjects were studied.
Results: The serum Ang-1 levels were significantly elevated in patients with asthma compared to control subjects
(293.9 ± 13.8 pg/mL vs. 248.3 ± 16.2 pg/mL, respectively, p = 0.04). The serum Ang-2 levels were not different between
the two groups. The areas under the curve (AUC) for serum angiopoietins revealed that the serum level of Ang-1 (0.68)
was more sensitive and specific than the serum Ang-2 level (0.55) for differentiating between patients with asthma and
control subjects. The serum Ang-1/Ang-2 ratio was correlated with the FEV1/FVC ratio (r = -0.312, p = 0.02), while serum
Ang-2 was correlated with body mass index.
Conclusions: Our results indicate that the serum Ang-1 levels were higher in asthma patients compared with healthy
subjects. As the Ang-1/Ang-2 ratio was related to lung function, the data suggest that serum angiopoietin is associated
with lung function in patients with asthma.
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Increased angiogenesis is a well-documented feature of
airway remodeling in asthma [1-6]. Angiogenesis is de-
fined as the formation of new blood vessels from pre-
existing endothelium. Airway remodeling [2] in asthmatic
patients involves a wide array of pathophysiological fea-
tures, including epithelial changes, increased smooth
muscle mass, increased numbers of activated fibroblasts/
myofibroblasts, subepithelial fibrosis, angiogenesis, alter-
ations in extracellular matrix components, and vascular
changes. Multiple cytokines, chemokines, and growth fac-
tors released from inflammatory and structural cells in air-
way tissue create a complex signaling environment that* Correspondence: jas877@schmc.ac.kr
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unless otherwise stated.drives these structural changes. Previous studies suggested
that neovascularization and microvascular leakage are
prominent in asthmatic airways [2-7]. Vascular endothelial
growth factor (VEGF) is one of the most potent proangio-
genic factors [8]. Angiogenesis can be initiated by en-
dogenous angiogenic factors released from mesenchymal
cells and/or inflammatory cells [9]. Under physiological
conditions, angiogenesis is controlled by the equilibrium
between the proendogenous and antiendogenous angio-
genic factors released from the extracellular matrix [10].
In experimental models, administration of angiopoietin-2
(Ang-2) provokes microvascular leakage in the lungs and
other organs [11,12], whereas Ang-1 protects against
microvascular leakage induced by VEGF, Ang-2, or inflam-
matory agents [13-16]. Ang-2 is released from endothelial
cells [17] and human monocytes [18], while various other
tissue cells produce Ang-1. Both Ang-1 and Ang-2 bind to
Tie2 receptor, which is abundantly expressed in lung endo-
thelium [19]. It was reported that Ang-1 and Ang-2 levelstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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asthmatics and mice [20-22]. Therefore, we examined the
serum levels of angiopoietins in patients with asthma and




We retrospectively studied clinical data on 35 asthma
patients (Table 1) who were registered in an asthma co-
hort of the Genome Research Center for Allergy and Re-
spiratory Diseases in Korea. All patients were recruited
from Soonchunhyang University, Bucheon Hospital.
Asthma diagnoses were based on GINA guidelines [23].
All subjects had a clinical diagnosis of asthma that was
supported by one or more of the following criteria: 1)
variability in the maximum diurnal peak expiratory flow of
greater than 20% over the course of 14 days, 2) an increase
in FEV1 of greater than 15% after the inhalation of 200-
400 μg of albuterol, or 3) a 20% reduction in FEV1 in
response to a provocative concentration of inhaled metha-
choline (PC20 methacholine) of less than 10 mg/mL. All
subjects underwent standardized assessments, which in-
cluded analyses of induced-sputum specimens, a complete
blood cell count with a differential count, IgE measure-
ment, chest posteroanterior radiography, allergy skin prick
tests, and spirometry. All data were collected at the time of
diagnosis, before the administration of asthma medication.
Asthmatic subjects matched to normal controls in
terms of age, sex, and body mass index (BMI) were se-
lected from among the asthma cohort of Bucheon Hos-
pital for inclusion in this study. The normal controlTable 1 Clinical and physiological variables in patients
with bronchial asthma and control subjects
Normal controls Asthmatic patients
Variables n = 20 n = 35
Age, yr 51.4 (±8.9) 46.6 (±13.7)
Sex (M/F) 13/7 15/20
Smoke (SM/ES/NS) 5/2/10 5/8/20
Atopy (Y/N) 6/14 17/18
Asthma period, yr 0 1.53 (±0.72)
IgE (pg/ml) 72.08 (±84.0) 260.11 (±514.0)
BMI (kg/m2) 23.72 (±2.89) 23.97 (±3.01)
FVC (%, predicted) 91.40 (±9.1) 73.00 (±14.6)*
FEV1 (%, predicted) 103.0 (±8.7) 74.0 (±16.6)*
FEV1/FVC % 86.0 (±4.9) 74.9 (±10.8)*
PC20 methacholine 23.87 (±5.05) 3.11 (±4.63)*
*p < 0.001 compared with control subjects.
Plus-minus values are mean ± S.D. PC20 methacholine; the concentration of
methacholine required to decrease the FEV1 by 20%, FEV1; forced expiratory
volume in one second. FVC; forced vital capacity. BMI; body mass index. SM;
smoker, ES; ex-smoker, NS; non-smoker.subjects were spouses of the patients or members of the
general population who answered negatively to a screen-
ing questionnaire regarding respiratory symptoms and
other allergic diseases, had a predicted FEV1 value greater
than 80%, a PC20 methacholine greater than 10 mg/mL,
and normal findings on simple chest radiographs. The ex-
clusion criteria included respiratory infection during spu-
tum induction, chronic obstructive pulmonary disease
(COPD), vocal cord dysfunction, obstructive sleep apnea,
Churg-Strauss syndrome, cardiac dysfunction, allergic
bronchopulmonary aspergillosis, and poor adherence to
treatment. The local research ethics committee of the
Soonchunhyang University Hospital Research Board ap-
proved the study protocol. All patients and control sub-
jects were recruited over a period of 3 months. Serum
samples were collected at the time of diagnosis before the
administration of asthma medication and at the time of
control subject recruitment to minimize bias due to the
storage time of the patient samples and the measurement
of serum angiopoietins.
Lung function analyses
Spirometry [24] was performed before and after broncho-
dilator use. Baseline FVC and FEV1 measurements were
obtained in the absence of bronchodilator use (within 8
h). Basal and post-bronchodilator FEV1 and FVC were
measured. We used a Vmax Series 2130 Autobox Spirom-
eter (Sensor Medics Corp., Yorba Linda, CA, USA) and
performed a calibration check every morning at 8 am.
Allergy skin tests
Skin prick tests were performed using 24 common inhal-
ant allergens, including dust mites (Dermatophagoides
farinae and Dermatophagoides pteronyssinus), cat fur,
dog fur, cockroaches, grass, tree, pollens, ragweed, and
Aspergillus species (Bencard Co.; Brentford, UK) [25].
Atopy was defined as either having a wheal reaction
from the allergen equal to or greater than the histamine
wheal (1 mg/mL) or at least 3 mm in diameter. Total
IgE was measured using the UniCAP system (Pharmacia
Diagnostics, Uppsala, Sweden).
BMI
The BMI of the subjects [26-28] was calculated as
weight (kg)/height (m2).
Mediator assays
Ang-1 and Ang-2 levels were assessed in serum super-
natant samples using ELISAs according to the manufac-
turers’ instructions. The minimum detectable dose of
Ang-1 and Ang-2 ranged from 1.36-10.3 pg/mL and 1.20-
21.3 pg/mL (R&D Systems, Minneapolis, MN, USA), re-
spectively. Blood was drawn to evaluate serum albumin
levels using laser nephelometry. All values were expressed
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variability values were 3.5% and 6.3%, respectively.
Statistical analyses
The data were double entered into a statistical software
package (SPSS, version 14.0; SPSS Inc., Chicago, IL, USA).
The data are expressed as means ± standard deviation (SD).
Group differences between the asthmatic patients and con-
trol subjects were compared using two-sample t-tests,
Mann-Whitney tests, or Pearson’s chi-square tests for nor-
mally distributed, skewed, or categorical data, respectively. A
value of p <0.05 was taken to indicate statistical significance.
Results
The serum Ang-1 levels were significantly elevated in
the patients with asthma compared to those in the con-
trol subjects (293.9 ± 13.8 pg/mL vs. 248.3 ± 16.2 pg/mL,
respectively, p = 0.04; Figure 1). The serum Ang-2 levels
did not differ between the two groups (7.35 ± 0.57 pg/mL
vs. 7.31 ± 0.80 pg/mL, respectively; Figure 1). The AUC for
serum angiopoietins indicated that the serum Ang-1 levels
(0.68) were more sensitive and specific than the serum
Ang-2 levels (0.55) for differentiating patients with asthma
from control subjects (Figure 2).
There were no differences between the two groups
in terms of atopy, IgE level, smoking status, or sex. The
FEV1, FVC, FEV1/FVC, and PC20 methacholine were lower
in patients with asthma compared to control subjects. The
serum Ang-1/Ang-2 ratio was correlated with the FEV1/
FVC ratio (all subjects: r = -0.298, p = 0.027; asthmatic
patients: r = -0.312, p = 0.02; Figure 3). Serum Ang-2 was
correlated with BMI (all subjects: r = -0.427, p = 0.001; asth-
matic patients: r = -0.353, p = 0.038; Figure 4). Serum Ang-1
and Ang-2 levels were not correlated with clinical parame-
ters such as atopy, IgE level, and sputum eosinophilia.
Discussion
Our results indicate that the serum Ang-1 levels were higher
in asthmatics than in healthy subjects, and that the serumFigure 1 Serum angiopoietin 1 (A) and angiopoietin 2 (B) levels in paAng-1/Ang-2 ratio was correlated with lung function, sug-
gesting that angiopoietins are useful markers for the diagno-
sis of asthma.
Angiogenesis and vascular remodeling are key events in
fundamental physiological processes, including growth and
development, wound healing, organ regeneration, inflamma-
tion, and reproduction [29-31]. Increased size and numbers
of bronchial blood vessels are also present, suggesting that
angiogenesis is an essential component of tissue growth and
remodeling in asthma [32]. Blood vessels are crucial for em-
bryonic organ growth and the repair of wounded tissues in
adults because they carry oxygen to the newly formed tissue.
Angiogenesis is an important event in the development of
allergic inflammation, as well as in the pathophysiology of
tissue remodeling in asthma [6].
Angiogenesis is tightly regulated by a number of factors
[28,33]. Ang-1 is predominantly expressed in perivascular
cells during development but is constitutively expressed in
adult tissues [34]. The role of Ang-2, the second Tie2 bind-
ing partner, appears to be more complex. In contrast to
Ang-1, Ang-2 is only minimally expressed (or not expressed
at all) in most normal adult tissues. However, it is strongly
and rapidly upregulated in endothelial cells at sites of inten-
sive vessel remodeling, including the female reproductive
system and tumors [35].
The bronchial submucosa of patients with asthma has
increased numbers of vessels in large as well as medium
and small airways, which occupy a larger percentage of
area than in normal subjects [5,36,37]. Airway vascular
remodeling and inflammation may be responsible for in-
creased bronchial blood flow [38] and exhaled breath
temperature gradients in patients with asthma [39].
Ang-1 inhibits vascular permeability without affecting
vascular morphology. Endothelial cells need to loosen the
interendothelial cell contacts to emigrate from their resi-
dent sites [40]. Ang-2, an inhibitor of Tie2 signaling, may
be involved in detaching smooth muscle cells and loosen-
ing the matrix [40]. Once the intracellular contacts have
been loosened, VEGF initiates endothelial networktients with asthma and healthy controls.
Figure 3 Association of the angiopoietin 1/angiopoietin 2 ratio with FEV1/FVC in patients with asthma.
Figure 2 Serum angiopoietin 1 and angiopoietin 2 receiver operating characteristic curves. Those plot points in the left uppermost region
represent more accurate values.
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Figure 4 Relationship between angiopoietin 2 and body mass index in patients with asthma.
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sels [40].
In patients, circulating Ang-2, VEGF, and von Willeb-
rand factor (VWF) levels are increased during ALI/
ARDS or sepsis [11,13,41]. High Ang-2 levels correlate
with impaired pulmonary gas exchange [11]. Circulating
Ang-2 is associated with pulmonary permeability edema,
and the occurrence and severity of ALI/ARDS in pa-
tients with and without sepsis [42]. The correlation of
Ang-2 with VWF suggests the activated endothelium as
a common source [42].
In our patients, the levels of circulating serum Ang-2
did not differ between normal controls and asthmatic
patients, whereas the serum Ang-1 levels were increased
in asthmatic patients. These results support the hypoth-
esis that high Ang-2 levels, which antagonize the pro-
tective role of Ang-1, are involved in the increased
pulmonary permeability that leads to asthma [11,13,41].
The serum Ang-1/Ang-2 ratio was related to the severity
of lung impairment, suggesting a contributory role for
Ang-1/Ang-2 in the pathogenesis of bronchial asthma.
However, additional studies, including serial serum and al-
veolar compartment measurements of Ang-1/Ang-2 and
blocking studies, are necessary to confirm this hypothesis.
The serum Ang-2 levels in our patients with asthma are
comparable to those reported in patients with severe
asthma by Tseliou et al. [20], who reported higher Ang-1
and Ang-2 levels in patients with severe asthma. Thisdiscrepancy may be explained by the patient recruitment
and serum sampling protocols used in our study. In ani-
mal models, Ang-1 levels were shown to be decreased in
asthma and to protect against airway inflammation and
hyperreactivity in asthma [43]. In contrast to the study of
Simon [43], the serum Ang-1 levels in the present study
were increased in patients with asthma compared to the
controls, suggesting a difference in angiopoietin-producing
cells between humans and other animals.
Interestingly, we found that serum Ang-2 was negatively
correlated with BMI, suggesting that obesity reduces the
serum levels of Ang-2 produced by endothelial cells and
monocytes, resulting in imbalanced angiopoietin func-
tion. This study has a number of limitations related to
the small number of patients and the retrospective na-
ture of the study. Therefore, additional studies are
needed of larger cohorts of asthma patients with differ-
ent disease severities.
Conclusions
The serum Ang-1 levels were higher in the asthmatic
subjects than in the controls, and the serum Ang-1/
Ang-2 ratio was correlated with lung function, indicating
that serum angiopoietins may aid in the diagnosis
of asthma.Competing interests
The authors declare that they have no competing interests.
Moon et al. BMC Pulmonary Medicine 2014, 14:143 Page 6 of 7
http://www.biomedcentral.com/1471-2466/14/143Authors’ contributions
MKY carried out the immunoassays, drafted the manuscript. LPH performed
the statistical analysis. PSW and PCS participated in the acquisition of clinical
data and in its design of the study. JAS conceived of the study, participated
in its design and coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.Acknowledgments
This research was supported by Basic Science Research Program through
the National Research Foundation of Korea (NRF) funded by the Ministry of
Education (2013R1A1A2005465) and Soonchunhyang University Research
Fund.
Received: 23 March 2014 Accepted: 18 August 2014
Published: 2 September 2014References
1. Corrigan CJ, Wang W, Meng Q, Fang C, Wu H, Reay V, Lv Z, Fan Y, An Y,
Wang YH, Liu YJ, Lee TH, Ying S: T-helper cell type 2 (Th2) memory T
cell-potentiating cytokine IL-25 has the potential to promote angiogenesis
in asthma. Proc Natl Acad Sci U S A 2011, 108:1579–1584.
2. Al-Muhsen S, Johnson JR, Hamid Q: Remodeling in asthma. J Allergy Clin
Immunol 2011, 128:451–462.
3. Kristan SS, Malovrh MM, Silar M, Kern I, Flezar M, Kosnik M, Suskovic S,
Korosec P: Airway angiogenesis in patients with rhinitis and controlled
asthma. Clin Exp Allergy 2009, 39:354–360.
4. Li X, Wilson JW: Increased vascularity of the bronchial mucosa in mild
asthma. Am J Respir Crit Care Med 1997, 156:229–233.
5. Hoshino M, Takahashi M, Aoike N: Expression of vascular endothelial
growth factor, basic fibroblast growth factor, and angiogenin
immunoreactivity in asthmatic airways and its relationship to
angiogenesis. J Allergy Clin Immunol 2001, 107:295–301.
6. McDonald DM: Angiogenesis and remodelling of airway vasculature in
chronic inflammation. Am J Respir Crit Care Med 2001, 164:39–45.
7. Puxeddu I, Berkman N, Nissim Ben Efraim AH, Davies DE, Ribatti D, Gleich
GJ, Levi-Schaffer F: The role of eosinophil major basic protein in angiogenesis.
Allergy 2009, 64:368–374.
8. Detoraki A, Granata F, Staibano S, Rossi FW, Marone G, Genovese A:
Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy 2010,
65:946–958.
9. Burgess JK, Boustany S, Moir LM, Weckmann M, Lau JY, Grafton K, Baraket M,
Hansbro PM, Hansbro NG, Foster PS, Black JL, Oliver BG: Reduction of
Tumstatin in asthmatic airways contributes to angiogenesis,
inflammation, and hyperresponsiveness. Am J Respir Crit Care Med 2010,
181:106–115.
10. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med
2005, 9:267–285.
11. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA,
Sukhatme VP: Excess circulating angiopoietin-2 may contribute to
pulmonary vascular leak in sepsis in humans. PLoS Med 2006, 3:e46.
12. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G,
Papapetropoulos A: Angiopoietin-2 causes inflammation in vivo by
promoting vascular leakage. J Pharmacol Exp Ther 2005,
314:738–744.
13. Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B, Mostoslavsky G,
Ingber DE, Sukhatme VP: Angiopoietin-1 requires P190RhoGAP to protect
against vascular leakage in vivo. J Biol Chem 2007, 282:23910–23918.
14. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, azer N, Holash J,
McDonald DM, Yancopoulos GD: Angiopoietin-1 protects the adult
vasculature against plasma leakage. Nat Med 2000, 6:460–463.
15. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C:
Protective role of angiopoietin-1 in endotoxic shock. Circulation 2005,
111:97–105.
16. Eklund L, Olsen BR: Tie receptors and their angiopoietin ligands are
contextdependent regulators of vascular remodelling. Exp Cell Res 2006,
312:630–641.
17. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W,
Thurston G, Augustin HG: The Tie-2 ligand angiopoietin-2 is stored in and
rapidly released upon stimulation from endothelial cell Weibel-Palade
bodies. Blood 2004, 103:4150–4156.18. Kranidioti H, Orfanos SE, Vaki I, Kotanidou A, Raftogiannis M, Dimopoulou I,
Kotsaki A, Savva A, Papapetropoulos A, Armaganidis A, Giamarellos-
Bourboulis EJ: Angiopoietin-2 is increased in septic shock: evidence for
the existence of a circulating factor stimulating its release from human
monocytes. Immunol Lett 2009, 125:65–71.
19. Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST, Chung LP: The
angiopoietins, tie2 and vascular endothelial growth factor are
differentially expressed in the transformation of normal lung to
nonsmall cell lung carcinomas. Lung Cancer 2000, 29:11–22.
20. Tseliou E, Bakakos P, Kostikas K, Hillas G, Mantzouranis K, Emmanouil P,
Simoes D, Alchanatis M, Papiris S, Loukides S: Increased levels of
angiopoietins 1 and 2 in sputum supernatant in severe refractory
asthma. Allergy 2012, 67:396–402.
21. Makinde TO, Agrawal DK: Increased expression of angiopoietins and Tie2
in the lungs of chronic asthmatic mice. Am J Respir Cell Mol Biol 2011,
44:384–393.
22. Kanazawa H, Asai K, Tochino Y, Kyoh S, Kodama T, Hirata K: Increased levels
of angiopoietin-2 in induced sputum from smoking asthmatic patients.
Clin Exp Allergy 2009, 39:1330–1337.
23. Global Initiative for Asthma (GINA): Global strategy for Asthma Management
and Prevention. NHLBI/WHO workshop report. Bethesda, MD: National
Institutes of Health, National Heart, Lung, and Blood Institute; 1995. NIH
publication no. 95-3659.
24. Park SW, Lee YM, Jang AS, Lee JH, Hwangbo Y, Kim DJ, Park CS:
Development of chronic airway obstruction in patients with
eosinophilic bronchitis: a prospective follow-up study. Chest 2004,
125:1998–2004.
25. Park CS, Kim YY, Kang SY: Collection between RAST and skin test for
inhalant offending allergens. J Korean Soc Allergol 1983, 3:1–9.
26. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck
A, Leitzmann MF: Overweight, obesity, and mortality in a large prospective
cohort of persons 50 to 71 years old. N Engl J Med 2006, 355(8):763–778.
27. McGee DL: Body mass index and mortality: a meta-analysis based on
personlevel data from twenty-six observational studies. Ann Epidemiol
2005, 15:87–97.
28. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in
obesity among US adults, 1999-2000. JAMA 2002, 288:1723–1727.
29. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003, 9:653–660.
30. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors.
Nat Med 2003, 9:669–676.
31. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial
growth factor (VEGF) and its receptors. FASEB J 1999, 13:9–22.
32. McDonald DM: Angiogenesis and remodeling of airway vasculature in
chronic inflammation. Am J Respir Crit Care Med 2001, 164(10 Pt 2):S39–S45.
33. Simon MP, Tournaire R, Pouyssegur J: The angiopoietin-2 gene of endothelial
cells is up-regulated in hypoxia by a HIF binding site located in its first in-
tron and by the central factors GATA-2 and Ets-1. J Cell Physiol 2008,
217:809–818.
34. Thurston G: Role of Angiopoietins and Tie receptor tyrosine kinases in
angiogenesis and lymphangiogenesis. Cell Tissue Res 2003, 314:61–68.
35. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D,
Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth
in tumors mediated by angiopoietins and VEGF. Science 1999,
284:1994–1998.
36. Salvato G: Quantitative and morphological analysis of the vascular bed in
ronchial biopsy specimens from asthmatic and non-asthmatic subjects.
Thorax 2001, 56:902–906.
37. Hashimoto M, Tanaka H, Abe S: Quantitative analysis of bronchial wall
vascularity in the medium and small airways of patients with asthma
and COPD. Chest 2005, 127:965–972.
38. Kumar SD, Emery MJ, Atkins ND, Danta I, Wanner A: Airway mucosal
blood flow in bronchial asthma. Am J Respir Crit Care Med 1998,
158:153–156.
39. Paredi P, Kharitonov SA, Barnes PJ: Faster rise of exhaled breath
temperature in asthma: a novel marker of airway inflammation? Am J
Respir Crit Care Med 2001, 165:181–184.
40. Paredi P, Barnes PJ: The airway vasculature: recent advances and clinical
implications. Thorax 2009, 64:444–450.
41. Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S, Dimopoulou I,
Sotiropoulou C: Angiopoietin-2 is increased in severe sepsis: correlation
with inflammatory mediators. Crit Care Med 2006, 35:199–206.
Moon et al. BMC Pulmonary Medicine 2014, 14:143 Page 7 of 7
http://www.biomedcentral.com/1471-2466/14/14342. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, van Hinsbergh
VWM, Groeneveld ABJ: Angiopoietin-2, permeability oedema, occurrence
and severity of ALI/ARDS in septic and non-septic critically ill patients.
Thorax 2008, 63:903–909.
43. Simoes DC, Vassilakopoulos T, Toumpanakis D, Petrochilou K, Roussos C,
Papapetropoulos A: Angiopoietin-1 protects against airway inflammation and
hyperreactivity in asthma. Am J Respir Crit Care Med 2008, 177:1314–1321.
doi:10.1186/1471-2466-14-143
Cite this article as: Moon et al.: Serum angiopoietin is associated with
lung function in patients with asthma: a retrospective cohort study.
BMC Pulmonary Medicine 2014 14:143.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
